You are here

Article Text

Article menu
Download PDFPDF
Education
Toxic corneal oedema associated with amantadine use
  1. A Pond1,
  2. M S Lee1,2,3,
  3. D R Hardten1,
  4. A R Harrison1,2,
  5. J H Krachmer1
  1. 1
    Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, USA
  2. 2
    Departments of Neurology and Otolaryngology, University of Minnesota, Minneapolis, Minnesota, USA
  3. 3
    Department of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA
  1. Dr M S Lee, MMC 493, 420 Delaware St SE, Minneapolis, MN 55455, USA; mikelee{at}umn.edu

http://dx.doi.org/10.1136/bjo.2007.135731

Statistics from Altmetric.com

    Amantadine HCl is an antiviral agent used to treat and prevent influenza A. It is also indicated for the treatment of Parkinsonism and drug-induced extrapyramidal symptoms.[1] Off-label uses include multiple sclerosis, Alzheimer disease and attention-deficit/hyperactivity disorder (ADHD). We report two patients with reversible, profound visual loss and corneal oedema associated with amantadine use.

    CASES

    Case 1

    A 12-year-old girl with generalised anxiety …

    View Full Text

    Footnotes

    • Funding: Unrestricted Grant from Research to Prevent Blindness, New York and the Minnesota Lions.

    • Competing interests: None.

    • Ethics approval: Ethics approval was provided by the Institutional Review Board at the University of Minnesota.

    • Patient consent: Obtained from the patient/parents.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    2009 BMJ Publishing Group

    Linked Articles

    • Education
      ANSWERS
      BMJ Publishing Group Ltd.BMA House, Tavistock Square, London, WC1H 9JR
      British Journal of Ophthalmology 2009; 93 413-413 Published Online First: 24 Feb 2009. doi: 10.1136/bjo.2007.135731a